Cargando…
Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union
This multicenter, observational drug utilization (DU) study (NCT01594996) investigated the profile of patients and specialist providers who prescribed extended release quetiapine fumarate (quetiapine XR) for treatment of major depressive disorder (MDD) across five European countries (Germany, Italy,...
Autores principales: | Brody, Robert S., Liss, Charles L., Wray, Heather, Kastango, Kari, Bryant, Allison, Fabre, Alban, Thuresson, Anneli |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805122/ https://www.ncbi.nlm.nih.gov/pubmed/29068794 http://dx.doi.org/10.1097/YIC.0000000000000202 |
Ejemplares similares
-
The management of schizophrenia: focus on extended-release quetiapine fumarate
por: Peuskens, Joseph
Publicado: (2011) -
Update on extended release quetiapine fumarate in schizophrenia and bipolar disorders
por: El-Khalili, Nizar
Publicado: (2012) -
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
por: Wang, Gang, et al.
Publicado: (2014) -
Branch retinal vein occlusion associated with quetiapine fumarate
por: Yong, Ku Chui, et al.
Publicado: (2011) -
Quetiapine N-oxide–fumaric acid (2/1)
por: Shen, Jin, et al.
Publicado: (2012)